GENMAB ASDK 1 news, videos and press releases - Page 4
For more news please use our advanced search feature.
GENMAB ASDK 1 - More news...
GENMAB ASDK 1 - More news...
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
- Major Shareholder Announcement
- Genmab to Present at Jefferies London Healthcare Conference
- Major Shareholder Announcement
- Genmab Announces Financial Results for the First Nine Months of 2023
- Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
- TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
- EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
- Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Financial Results for the First Half of 2023
- Genmab Updates 2023 Financial Guidance
- Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
- Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
- Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
- Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
